EUVIMEDEUVIMED entdecken
Open Access

Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease

Dinah Foer iD, Taneem Amin, Jun Nagai iD, Yumi Tani iD, Chunli Feng, Tao Liu iD, Dawn C Newcomb, Juying Lai, Hiroaki Hayashi, William E Snyder, Alanna McGill, Anabel Lin und 4 weitere

The Journal of Immunology · 15.12.2023 · 211 (12) · 1806-1813

DOI: 10.4049/jimmunol.2300102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 23.10.2023. Verfasst von Dinah Foer und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, MA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Asthma, Aspirin-Induced, Asthma. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Platelets are key contributors to allergic asthma and aspirin-exacerbated respiratory disease (AERD), an asthma phenotype involving platelet activation and IL-33–dependent mast cell activation. Human platelets express the glucagon-like peptide-1 receptor (GLP-1R). GLP-1R agonists decrease lung IL-33 release and airway hyperresponsiveness in mouse asthma models. We hypothesized that GLP-1R agonists reduce platelet activation and downstream platelet-mediated airway inflammation in AERD. GLP-1R expression on murine platelets was assessed using flow cytometry. We tested the effect of the GLP-1R agonist liraglutide on lysine-aspirin (Lys-ASA)–induced changes in airway resistance, and platelet-derived mediator release in a murine AERD model. We conducted a prospective cohort study comparing the effect of pretreatment with liraglutide or vehicle on thromboxane receptor agonist-induced in vitro activation of platelets from patients with AERD and nonasthmatic controls. GLP-1R expression was higher on murine platelets than on leukocytes. A single dose of liraglutide inhibited Lys-ASA–induced increases in airway resistance and decreased markers of platelet activation and recruitment to the lung in AERD-like mice. Liraglutide attenuated thromboxane receptor agonist-induced activation as measured by CXCL7 release in plasma from patients with AERD and CD62P expression in platelets from both patients with AERD (n = 31) and nonasthmatic, healthy controls (n = 11). Liraglutide, a Food and Drug Administration–approved GLP-1R agonist for treatment of type 2 diabetes and obesity, attenuates in vivo platelet activation in an AERD murine model and in vitro activation in human platelets in patients with and without AERD. These data advance the GLP-1R axis as a new target for platelet-mediated inflammation warranting further study in asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Asthma, Aspirin-InducedAsthmaHumansMiceAnimalsLiraglutideGlucagon-Like Peptide-1 ReceptorInterleukin-33Prospective StudiesPlatelet ActivationAspirinInflammationReceptors, ThromboxaneLysine

Substanzen

LiraglutideGlucagon-Like Peptide-1 ReceptorInterleukin-33AspirinReceptors, Thromboxaneacetylsalicylic acid lysinateLysine

Autor:innen und Institutionen

  • Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
  • Harvard Medical School, Boston, MA.
  • Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN.
  • Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN.
  • Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
  • United States Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN.

ORCID-Profile: Dinah Foer, Jun Nagai, Yumi Tani, Tao Liu, Tanya M Laidlaw, Joshua A Boyce, Katherine N Cahill

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NCATS NIH HHS
  • HHS | NIH | National Heart, Lung, and Blood Institute
  • HHS | NIH | National Institute of Allergy and Infectious Diseases

Zitieren

APA

Foer, D., Amin, T., Nagai, J., Tani, Y., Feng, C., Liu, T., Newcomb, D. C., Lai, J., Hayashi, H., Snyder, W. E., McGill, A., Lin, A., Laidlaw, T. M., Niswender, K. D., Boyce, J. A., & Cahill, K. N. (2023). Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease. The Journal of Immunology, 211(12), 1806-1813. https://doi.org/10.4049/jimmunol.2300102

Vancouver

Foer D, Amin T, Nagai J, Tani Y, Feng C, Liu T, et al. Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease. The Journal of Immunology. 2023;211(12):1806-1813. doi:10.4049/jimmunol.2300102

BibTeX
@article{Foer2023,
  author = {Foer, Dinah and Amin, Taneem and Nagai, Jun and Tani, Yumi and Feng, Chunli and Liu, Tao and Newcomb, Dawn C and Lai, Juying and Hayashi, Hiroaki and Snyder, William E and McGill, Alanna and Lin, Anabel and Laidlaw, Tanya M and Niswender, Kevin D and Boyce, Joshua A and Cahill, Katherine N},
  title = {Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease},
  journal = {The Journal of Immunology},
  year = {2023},
  volume = {211},
  number = {12},
  pages = {1806--1813},
  doi = {10.4049/jimmunol.2300102}
}
Kostenlos starten →